Delivered Strong Financial and Operational Performance

**TOTAL NET SALES**

$46.2B

Consistent with prior year or, an increase of 3% when excluding foreign exchange

7% In-Line Brand YoY% growth

87% New Product Portfolio* YoY% growth

Potential for risk-adjusted sales of $10-$13B revenues in 2025

Potential for $25B+ of non-risk-adjusted revenues in 2030

GAAP EPS\(^1\) $2.95

Non-GAAP EPS\(^{1,2}\) $7.70

---

**Significant Pipeline Advancement in 2022**

18 approvals in the US, EU and Japan

9 approvals for Opdivo; Opdivo plus Yervoy

5 positive registrational topline readouts

$9.5B invested in research and development

**Launched 3 First-In-Class Medicines**

- **Opdualag**: For metastatic melanoma
- **CAMZYOS**: For obstructive hypertrophic cardiomyopathy
- **SOTYKTU**: For moderate to severe plaque psoriasis

**Strategically Positioned for Multiple Waves of Innovation**

9 new products launched over ~3 years\(^3\)

15+ additional indications over ~3 years\(^3\)

6 high potential mid-late stage registrational assets across therapeutic areas

50+ early-stage assets in development

**Balanced Approach to Capital Allocation**

$13.1B in cash flow from operating activities

Reduced debt by ~$5B

 Returned cash to shareholders $12.6B\(^4\)

---

* New Product Portfolio includes Reblozyl® (luspatercept-aamt), Inrebic® (fedratinib), Onureg® (azacitidine tablets), Zeposia® (ozanimod), Breyona® (lisocabtagene maraleucel), Abecma® (idecabtagene vicleucel), Opdualag® (relatlimab plus nivolumab), Camzyos® (mavacamten) and Sotyktu™ (deucravacitinib).

\(^1\) GAAP and non-GAAP EPS include the net impact of Acquired IPRD charges and licensing income of ($0.24) per share for the full year 2022. Acquired IPRD refers to certain in-process research and development (“Acquired IPRD”) charges resulting from upfront or contingent milestone payments in connection with asset acquisitions or licensing of third-party intellectual property rights.

\(^2\) This Non-GAAP amount excludes certain costs, expenses, gains and losses and other specified items. A reconciliation of GAAP to non-GAAP measures can be found on our website at bms.com. See, “Quarterly package of financial Information” available on bms.com/investors for information on the list of specified items excluded from Non-GAAP EPS.

\(^3\) Portfolio achievements from 2H 2019-2022.

\(^4\) Includes $4.6 billion for dividends paid and $8.0 billion for common stock repurchases.